Skip to content
Elizabeth Holmes- Case Archive
personpersonJohn C. BosticJohn C. BosticAssistant United States attorney and member of the prosecution team in the Elizabeth Holmes trial.← All People
ProsecutionU.S. Attorney's Office, Northern District of California

John C. Bostic

Assistant United States attorney and member of the prosecution team in the Elizabeth Holmes trial.

AppearedFederal Criminal Trial
6,366 lines·95 proceedings

About

John C. Bostic conducted prosecution examinations concerning laboratory performance, patient results, investor reliance, company communications, and wire transfers. Across those phases, he used emails, reports, presentations, and testing records to develop the contrast between Theranos's external claims and the limitations or concerns witnesses described.

With Erika Cheung, Bostic developed evidence about limited Edison testing, reliance on third-party analyzers, validation and quality-control failures, outlier removal, and internal warnings. His questioning of Audra Zachman and Erin Tompkins focused on conflicting HCG results and a reactive HIV screening followed by a negative test. His direct and redirect examination of Adam Rosendorff addressed assay discrepancies, patient complaints, proficiency testing, management control, and the laboratory director's reasons for preserving emails and leaving. After cross-examination challenged Rosendorff's motives, responsibility, and signed validation reports, Bostic's redirect distinguished validation from later clinical performance and returned to HCG accuracy, quality control, and the gap between regulatory responsibility and operational authority.

Bostic also examined James Mattis, Christopher Lucas, Alan Eisenman, and Roger Parloff about statements, communications, and materials that informed military support, investments, or a published profile, including representations about analyzer capabilities, fingerstick testing, third-party equipment, business performance, and military use. In Daniel Edlin's examinations, he developed evidence about staged demonstrations, concealed errors, selective reporting, third-party processing, military-project limits, and Holmes's review of external materials. Roberto Amenta's examination supplied Fedwire records tracing six transfers to Theranos across state lines.

Bostic also argued the admissibility of Theranos emails and Parloff material; the court required exhibit-specific foundations and limited the defense's customer-survey evidence. In rebuttal closing, Bostic argued that Holmes knowingly presented future hopes as existing capabilities, answered the defense's good-faith and trade-secret theories, and asked the jury to return guilty verdicts.

Trial Record (95)

FederalFederal Criminal TrialAug 31, 2021 – Jan 3, 2022

John C. Bostic served on the prosecution team and conducted examinations that connected Theranos's testing limits and internal warnings to patient, investor, and media representations. In rebuttal closing, he argued that Holmes had presented hoped-for capabilities as present reality and urged guilty verdicts.

Day 6

ProceduralEmail Exhibit Admissibility Hearing1highlight17lines spoken

Summary

Defense challenged Theranos email exhibits on hearsay, foundation, and relevance grounds; the court allowed foundation for Exhibits 1287 and 1289 and deferred the remaining dispute.

Highlights (1)

Quote“THE GOVERNMENT SHOULD BE ALLOWED TO SHOW WHAT WAS HAPPENING AT THE COMPANY, MS. HOLMES'S KNOWLEDGE OF WHAT WAS HAPPENING AT THE COMPANY. THOSE TWO THINGS DON'T NECESSARILY NEED TO HAPPEN SIMULTANEOUSLY.”— John C. BosticThe statement captures the prosecution's strategy of combining evidence about company events with separate evidence concerning Holmes's knowledge.Open in transcript →

Day 7

sidebarSidebar on Relevance of Cheung's Nonprofit Work1highlight8lines spoken

Summary

The court excluded testimony about Erika Cheung's nonprofit work but allowed a narrower concluding question about her current work.

Highlights (1)

Quote“UNDERSTOOD. I WOULD SAY THAT HER ACTIONS AFTERWARDS SPEAK TO HER STATE OF MIND DURING THE RELEVANT TIME PERIOD, BUT IF NEITHER PARTY GOES INTO THIS, THAT'S FINE. I DON'T THINK IT'S ESSENTIAL THAT THE JURY HEARS ABOUT IT.”— John C. BosticThe prosecution stated its relevance theory but conceded that the jury did not need to hear the proposed nonprofit testimony.Open in transcript →
CrossErika Cheung — CrossErika CheungLance A. Wade7lines spoken

Summary

Defense counsel emphasized Theranos's trained laboratory teams, formal validation reports, multiple approvals, and written operating procedures while narrowing Cheung's personal expertise. Cheung agreed that QC preceded patient testing but maintained that validation was sometimes compressed, written procedures differed from practice, and frequent reader failures required extensive recalibration.

Day 8

CrossErika Cheung — CrossErika CheungLance A. Wade8lines spoken

Summary

Defense counsel used laboratory procedures, email chains, workflow improvements, and a sample-volume patent to emphasize Theranos's monitoring and remediation systems and to narrow Cheung's expertise. Cheung nevertheless maintained that the vitamin D SOP was not followed, confirmed that hepatitis C was not run on Edison after her concerns, and described Edison as a one-patient, one-test device.

Day 9

Day 10

Day 11

Day 12

Day 13

CrossAdam Rosendorff — CrossAdam RosendorffLance A. Wade11lines spoken

Summary

Defense counsel challenged Adam Rosendorff with inspection records, compliance emails, signed Edison validation reports, quality-system data, and proficiency-testing records. Rosendorff acknowledged inspection cooperation, assay approvals, and predicate-device proficiency testing while maintaining that later Edison performance, incident management, and alternative testing remained deficient.

Day 14

CrossAdam Rosendorff — CrossAdam RosendorffLance A. Wade21lines spoken

Summary

Defense counsel challenged Adam Rosendorff with AAP policies, laboratory emails, physician-call records, and meeting calendars. Rosendorff accepted substantial laboratory-director responsibility but maintained that proficiency-testing implementation and data access were incomplete and that management sometimes exceeded its qualifications.

Day 15

Day 16

ProceduralLaboratory-Comparison Testimony Evidence Hearing10lines spoken

Summary

The court struck Dr. Adam Rosendorff's comparison of Theranos with other laboratories and ordered the jury to disregard the question and answer. It rejected the defense's request to explore specific problems at his former laboratories, citing Rule 403 and the danger of collateral mini-trials.

Day 18

Day 19

Day 20

ProceduralExhibit 1496 Admissibility Hearing5lines spoken

Summary

The defense challenged Exhibit 1496, an email reporting comments from a military meeting, while the prosecution argued it bore on Holmes's knowledge and state of mind; the court left admissibility unresolved pending context and foundation.

Day 21

DirectDaniel Edlin — DirectDaniel EdlinJohn C. Bostic333lines spoken

Summary

Daniel Edlin described concealed demonstration errors, selective removal or reframing of test results, third-party processing, and internal technical problems. He also linked Holmes to report review, revised external communications, and detailed approval of website content while qualifying the limits of his own technical knowledge.

Day 22

CrossDaniel Edlin — CrossDaniel EdlinKevin M. Downey18lines spoken

Summary

Defense counsel used Daniel Edlin's resumed cross-examination to characterize Theranos's military projects as customized evaluations and its demonstrations as varied, labeled processes distinct from clinical testing. Edlin denied deceptive intent but maintained limits on his technical knowledge and confirmed that SOCOM never performed its planned experiment.

CrossDaniel Edlin — Cross (Resumed)Daniel EdlinKevin M. Downey23lines spoken

Summary

Daniel Edlin described Theranos's collaborative process for sourcing, reviewing, tailoring, and revising investor, website, media, and patient-facing claims. The court admitted numerous supporting emails and presentations, excluded a collective of customer-feedback reports on relevance grounds, and admitted an email concerning an external technology advisory board.

RedirectDaniel Edlin — RedirectDaniel EdlinJohn C. Bostic221lines spoken

Summary

Daniel Edlin distinguished Theranos's military evaluations and artificial scenarios from clinical deployment, confirmed that demonstration software hid errors and that results were selectively reported, and connected Holmes to technology information and final review of external materials. He said repeated failures to demonstrate the technology contributed to his departure.

Day 24

Day 25

Day 26

ProceduralHearing on Roger Parloff Testimony and Subpoena1highlight4lines spoken

Summary

The court narrowed but did not resolve disputes over Roger Parloff's anticipated contextual testimony, recordings, and subpoenaed materials, deferring further argument until the next morning.

Highlights (1)

Quote“WE DO NOT INTEND TO PLAY THE ENTIRETY OF THE RECORDINGS. THAT WOULD TAKE MORE THAN A TRIAL DAY TO PUT IN FRONT OF THE JURY.”— John C. BosticThe prosecution previewed its planned presentation of selected statements rather than the complete recordings.Open in transcript →

Day 27

Day 28

Day 29

Day 31

Day 32

CrossAlan Eisenman — CrossAlan EisenmanKevin M. Downey16lines spoken

Summary

Defense counsel used investor emails, prior statements, and Eisenman's communications with prosecutors during his ongoing testimony to challenge his recollection and credibility. Eisenman maintained that Theranos withheld information and that Balwani encouraged his 2013 investment, while acknowledging limits on his information rights and an email to the prosecution after a no-contact instruction.

CrossAlan Eisenman — Cross (Resumed)Alan EisenmanKevin M. Downey7lines spoken

Summary

Defense counsel confronted Alan Eisenman with written risk warnings, investment agreements, possible share-sale opportunities, and his contacts with the prosecution. Eisenman acknowledged the documents and market inquiries but maintained that the warnings conflicted with earlier representations, that proposed company offers were not completed, and that he lacked adequate financial information to decide whether to sell.

Day 33

Day 34

Day 35

Day 36

ProceduralRule 29 Motion and Evidentiary Record Matters4lines spoken

Summary

The defense renewed challenges to the CMS report, Erin Tompkins's HIV-result evidence, and evidence affected by the unavailable LIS database. Holmes also made a Rule 29 motion, which the court took under submission, and the court limited the defense's patent summary to applications filed through 2016 before the defense called Trent Middleton.

Day 39

ProceduralHearing on Renewed Motion to Admit Exhibit 142591highlight5lines spoken

Summary

The defense renewed its request to admit the E.T. test-results email as a business record. The government raised embedded-hearsay and foundation concerns, and the court deferred a ruling while considering redaction and further review.

Highlights (1)

Quote“A HEARSAY STATEMENT IS NOT A WAY TO CORRECT THE RECORD EVEN IF THE RECORD WERE IMBALANCED AS IT STANDS TODAY.”— John C. BosticThe government stated its central objection to using the email as a substitute for testimony from the physician whose views it purported to report.Open in transcript →

Day 40

Day 47

RebuttalRebuttal Closing Argument by the ProsecutionJohn C. Bostic2highlights28lines spoken

Summary

The prosecution argued that Holmes knowingly presented hoped-for capabilities as present reality, rebutted the defense's good-faith and trade-secret theories, and urged guilty verdicts before the court instructed the jury and sent it to deliberate.

Highlights (2)

Quote“THE DISEASE THAT PLAGUED THERANOS WASN'T A LACK OF EFFORT, IT WAS A LACK OF HONESTY, AND IT WASN'T AT THE BOTTOM OF THE GROUND LEVEL OF THE COMPANY, IT WAS AT THE TOP AS THE EVIDENCE HAS SHOWN.”— John C. BosticThis sentence condensed the prosecution's rebuttal theory by distinguishing employee effort from alleged dishonesty by company leadership.Open in transcript →
Quote“THIS IS HOW YOU WRITE SENTENCES ABOUT WHAT HASN'T HAPPENED YET. EVERYBODY KNOWS THIS.”— John C. BosticThe prosecutor used this observation to contrast a scientist's forward-looking description of System 4.0 with present-tense representations attributed to Holmes.Open in transcript →